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Abstract
Background: Non-nutritive sweeteners (NNS), especially in form of diet soda, have been linked to metabolic
derangements (e.g. obesity and diabetes) in epidemiologic studies. We aimed to test acute metabolic effects of
NNS in isolation (water or seltzer) and in diet sodas.
Methods: We conducted a four-period, cross-over study at the National Institutes of Health Clinical Center
(Bethesda, Maryland). Thirty healthy adults consumed 355 mL water with 0 mg, 68 mg, 170 mg, and 250 mg
sucralose, and 31 individuals consumed 355 mL caffeine-free Diet Rite Cola™, Diet Mountain Dew™ (18 mg
sucralose, 18 mg acesulfame-potassium, 57 mg aspartame), and seltzer water with NNS (68 mg sucralose and
41 mg acesulfame-potassium, equivalent to Diet Rite Cola™) in randomized order, prior to oral glucose tolerance tests.
Blood samples were collected serially for 130 min. Measures included GLP-1, GIP, glucose, insulin, C-peptide, glucose
absorption, gastric emptying, and subjective hunger and satiety ratings.
Results: Diet sodas augmented active GLP-1 (Diet Rite Cola™ vs. seltzer water, AUC, p = 0.039; Diet Mountain Dew™ vs.
seltzer water, AUC, p = 0.07), but gastric emptying and satiety were unaffected. Insulin concentrations were nominally
higher following all NNS conditions without altering glycemia. Sucralose alone (at any concentration) did not affect
metabolic outcomes.
Conclusions: Diet sodas but not NNS in water augmented GLP-1 responses to oral glucose. Whether the trends
toward higher insulin concentrations after NNS are of clinical importance remains to be determined. Our findings
emphasize the need to test metabolic effects of NNS after chronic consumption.
Trial registration: The data for this manuscript were gathered from clinical trial #NCT01200940.
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Background
Several large epidemiologic studies have suggested adverse
metabolic effects resulting from non-nutritive sweeteners
(NNS) consumption, surprisingly similar to sugar intake.
These include weight gain [1], central adiposity [2], meta-
bolic syndrome [3], and cardiovascular disease [4]. In two
recent studies, consumption of regular and diet soft drinks
was associated with a similarly increased risk of develop-
ing type 2 diabetes [5, 6] and non-alcoholic fatty liver
disease [7], though associations were no longer signifi-
cant among diet beverage consumers after adjustment
for body weight. This finding suggests that obesity is
the link between NNS and metabolic disease. In contrast
to epidemiologic findings, randomized controlled trials
with NNS have shown neutral effects or even possible
weight management benefits following NNS consumption
[8, 9]. This may be especially true when sugar is replaced
with NNS [10]. An excellent overview of the existing
controversies has recently been published [11].
While reverse causality likely contributes to the ob-
served epidemiologic association between NNS use and
weight [12], alternative explanations include behavioral
and cognitive mechanisms such as greater energy in-
take after ‘saved’ calories due to choosing NNS [12] and
a disruption of the predictive relationship between
sweet taste perception and caloric intake [13]. Further-
more, NNS have been shown to induce less central reward
compared to caloric sugars [14], potentially leading to
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continued seeking of palatable food. Recently, alterations
of the gut microbiome have been reported after NNS ex-
posure [15, 16], promoting greater energy harvest [17].
Based on in vitro studies, it has also been suggested that
NNS may up-regulate adipogenesis [18]. It is important to
note that NNS induced microbiome changes have only
been reported in one small human study and changes in
adipose tissue have not yet been replicated in humans.
Another plausible explanation is direct stimulation of
insulin secretion in response to binding of NNS to sweet
taste receptors (T1R2/T1R3) on pancreatic beta-cells.
This has been documented in vitro [19, 20] and is sup-
ported by results of a small clinical trial showing in-
creased insulin levels following NNS exposure in
humans [21]. Sweet taste receptors are also found in
the intestine [22], where they modulate various gut hor-
mone responses, including glucagon-like-peptide 1 (GLP-1)
secreted from enteroendocrine L-cells [23] and gastric in-
hibitory peptide (GIP) secreted from enteroendocrine K-
cells [24]. We previously demonstrated that ingestion of a
diet soda (Diet Rite Cola™) sweetened with sucralose and
acesulfame-potassium, administered prior to an oral
glucose load, resulted in a 34 % increase in GLP-1 se-
cretion in comparison to unflavored carbonated water.
This was shown both in healthy adolescents and young
adults [25] and in youth with type 1 diabetes [26].
Herein we report the results of a randomized same-
subject crossover study testing the effects of NNS on
glycemia, insulin, and incretin responses in healthy
adults. In the first set of experiments (study arm 1), we
evaluated three doses of sucralose mixed in water to fur-
ther test our original hypothesis that sucralose was the ac-
tive ingredient in Diet Rite Cola™ responsible for the
previously observed increase in glucose-dependent GLP-1
secretion. In the second set of experiments (study arm 2),
we tested whether two combinations of NNS in diet sodas
and in seltzer water increase GLP-1 secretion.
Methods
Sixty-one healthy adults (30 participants in study arm 1
and 31 participants in arm 2) were enrolled. All subjects
provided written informed consent. The protocol was
approved by the Institutional Review Board of the Na-
tional Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) (NCT #01200940, Metabolic Effects
of Non-nutritive Sweeteners). Inclusion criteria were
age between 18 and 45 years and no known active med-
ical conditions. Exclusion criteria included diabetes,
pregnancy, lactation, and active medication use, other
than oral contraceptives.
Study participants arrived at the NIH Clinical Center
at approximately 8 am following a ten hour fast. They
were instructed to avoid foods and beverages containing
NNS, acetaminophen, and alcohol for two days prior to
each study visit and to maintain a similar diet and physical
activity level. Diet and physical activity during the 24 h
prior to each study visit were recorded. Habitual NNS in-
take was assessed with a questionnaire and individuals
were categorized based on the frequency of NNS use
(whether in foods or beverages): at least once daily, less
than daily but at least once per month, or never. In both
study arms, visits were scheduled on four separate days,
approximately one week apart to avoid carryover effects
from the prior visit and to avoid any significant changes
in body weight or metabolic parameters.
Block randomization (block size 24) based on a random
number table was used to assign each subject to the four
test beverage conditions. In study arm 1, subjects were
randomized to consume 355 mL water mixed with a su-
cralose dose of 0 mg (plain water control), 68 mg, 170 mg,
or 250 mg prior to an oral glucose tolerance test (OGTT).
In study arm 2, subjects were randomized to consume
355 mL (standard 12 ounce can) seltzer water (control),
355 mL caffeine-free Diet Rite Cola™ sweetened with
68 mg sucralose and 41 mg acesulfame-potassium, 355 mL
caffeine-free Diet Mountain Dew™ sweetened with 18 mg
sucralose, 18 mg acesulfame-potassium and 57 mg aspar-
tame, or 68 mg sucralose and 41 mg acesulfame-potassium
in 355 mL of seltzer water prior to an OGTT. Study proce-
dures are summarized in Fig. 1. Composition of the diet
sodas are presented in Additional file 1: Table S1.
Baseline blood samples were drawn at −10 min, after
which subjects consumed the assigned test beverage in
2–3 min. At time 0 min, a second blood sample was
obtained, after which subjects ingested a standard oral
glucose load (75 g glucose) mixed with 1450 mg acet-
aminophen and 7.5 g 3-O-methylglucose. Blood samples
were drawn at 10, 20, 30, 60, 90, and 120 min following
consumption of the glucose load. Satiety questionnaires
were administered at baseline, immediately following con-
sumption of the glucose load and after 30, 60, 90, and
120 min.
Study data were collected and managed using REDCap
(Research Electronic Data Capture) hosted at Vanderbilt
University.
Measures
Active GLP-1 was measured by enzyme-linked immuno-
sorbent assay (Millipore, Billerica MA, USA). The lowest
detectable level of active GLP-1 was 6.56 pmol/L (inter-
assay CV 8 % and intra-assay CV 7 %). In study arm 1,
GIP was measured by enzyme-linked immunosorbent
assay (Millipore, Billerica MA, USA). The lowest detect-
able level of GIP was 8.2 pg/mL inter-assay CV 1.8–6.1 %
and intra-assay CV 3.0–8.8 %). In study arm 2, GIP was
measured using the Milliplex gut hormone kit based on
Luminex technology (EMD Millipore, Billerica MA, USA).
The lowest detectable level for GIP was 0.2 pg/mL
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(inter-assay CV 7.0 % and intra-assay CV 5.1 %). DPP-
IV inhibitor was added to blood collection tubes prior
to sample collection for analysis of GLP-1 and GIP. In
both study arms, insulin was measured using an ELISA
(R&D Systems, Minneapolis, MN, intra-assay CV 1.9 %
and inter-assay CV 4.1 %, assay range 15.6–500 pmol/L).
Serum glucose was determined using the glucose oxidase
method (inter-assay CV 3.9 % at 2.4 mmol/L and 1.2 % at
22.1 mmol/L; intra-assay CV 2.9 % at 2.4 mmol/L and
0.4 % at 22.1 mmol/L). C-peptide was measured by
electrochemiluminescence immunoassay. Normal fast-
ing range was 0.9–7.1 ng/mL in study arm 1 and 1.1–
5.0 ng/mL in study arm 2. Glucose absorption was
measured using 3-O-methylglucose (3-OMG, 7.5 g ad-
ministered with the glucose load), which is an inert,
non-metabolizable glucose analog. The appearance of
3-OMG in blood can thus be used as a proxy measure
of the rate of intestinal glucose absorption [27]. Acet-
aminophen appearance in the blood was used as a proxy
measure of the rate of gastric emptying [28]. 3-OMG and
acetaminophen were analyzed by gas chromatography–
mass spectrometry-(GC-MS) using a deuterated analyte
as internal standard. Plasma was deproteinated, dried,
and derivatized with methylboronic acid in pyridine for
3-OMG analysis. Acetaminophen was purified from acid-
ified plasma by solid phase extraction, then silylated prior
to analysis. All assays were performed in duplicate. Hun-
ger and satiety were measured using 100 mm visual
analog scales.
Statistical analysis
The primary end-point in study arm 1 was the difference
in glucose-stimulated active GLP-1 area-under-the-curve
(AUC) following ingestion of 68 mg of sucralose and
glucose-stimulated active GLP-1 secretion after the un-
sweetened water control. In study arm 2, our primary
outcome was the difference between glucose-stimulated
active GLP-1 AUC after ingestion of Diet Rite Cola™ and
glucose-stimulated active GLP-following the unsweetened
seltzer water control. Sample sizes were determined based
on our prior study [25], where ingestion of Diet Rite Cola™
augmented glucose-stimulated GLP-1 response compared
to an unsweetened seltzer water control. The difference in
glucose-stimulated insulin secretion following ingestion of
Diet Rite Cola™ compared to ingestion of seltzer water
was evaluated as a secondary outcome.
Fig. 1 Following a screening visit, subjects were randomized to consume either 355 mL water mixed with a sucralose dose of 0 mg (plain
water control), 68 mg, 170 mg, or 250 mg (study arm 1) or 355 mL seltzer water (control), 355 mL caffeine-free Diet Rite Cola™ sweetened
with 68 mg sucralose and 41 mg acesulfame-potassium, 355 mL caffeine-free Diet Mountain Dew™ sweetened with 18 mg sucralose, 18 mg
acesulfame-potassium and 57 mg aspartame or 68 mg sucralose and 41 mg acesulfame-potassium in 355 mL of seltzer water (study arm 2)
prior to an OGTT
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Descriptive statistics were calculated for each outcome
of interest during each of the four test visits in both
study arms. Incremental AUC was calculated using the
trapezoidal method. Peak was calculated as the maximum
value for each variable of interest over the 120-min time
course and occurred at different time points (e.g. at
20 min or 30 min) for different individuals. Thus, peak
values presented in Tables 2 and 3 differ slightly from
those depicted in the response curves presented in Fig. 2
and Fig. 3. Differences between the mean peak and AUC
in the four conditions were first assessed using repeated-
measures ANOVA, and post-hoc Dunnett’s tests were
used for pairwise comparisons, where repeated-measures
ANOVA indicated a trend for difference between the
groups. AUC values that were not normally distributed
were log-transformed before analyses. No adjustments
were made to account for multiple comparisons. Linear
mixed modeling was used to account for fixed and ran-
dom effects, given the same-subject crossover design of
the study.
Results
Characteristics of the study participants at baseline are
shown in Table 1. Study participants were similar in age
and gender, but more ethnically and racially diverse in
study arm 2. Overall NNS consumption was low in both
arms relative to the general population [29] with slightly
higher consumption in study arm 2. The mean BMI was
similar (25.8 ± 4.2 kg/m2 and 26.3 ± 7.5 kg/m2, respect-
ively), but baseline insulin, C-peptide and HOMA were
higher in study arm 2.
No statistically significant differences in active GLP-1,
GIP, glucose, insulin, or C-peptide were observed when
sucralose (at varying doses mixed in water) was admin-
istered before the OGTTs in study arm 1 (Table 2). In
contrast, active GLP-1 AUC was higher following Diet
Rite Cola™ (p = 0.04), and tended to be higher following
Diet Mountain Dew™ (p = 0.07) (Fig. 2, Table 3), but
not following the preload containing sucralose and
acesulfame-potassium mixed in seltzer water. GIP re-
sults following Diet Rite Cola™ showed a similar trend,
but did not reach statistical significance (peak p = 0.07).
Glucose concentrations were indistinguishable between
the four conditions (Fig. 3, Table 3). Both peak insulin and
insulin AUC were 17 to 25 % higher after Diet Rite Cola™,
Diet Mountain Dew™, and sucralose and acesulfame-
potassium in seltzer water pre-treatments, but did not
reach statistical significance. AUCs and peaks for active
GLP-1, GIP, glucose, insulin, and C-peptide following
Diet Rite Cola™, Diet Mountain Dew™, sucralose and
acesulfame-potassium in seltzer water, and seltzer water
pre-treatment are shown in Table 3.
Rates of gastric emptying and intestinal glucose ab-
sorption were not different following Diet Rite Cola™
(Additional file 2: Figure S1) compared to seltzer
water and subjective hunger and satiety ratings were
similar between all test conditions (data not shown).
Intestinal glucose absorption, rate of gastric emptying,
and subjective hunger and satiety ratings were also
similar following all four sucralose pre-treatment con-
ditions (data not shown).
Discussion
Our results demonstrate that a single exposure to a
beverage containing sucralose, acesulfame-potassium,
and other ingredients prior to an oral glucose load



































Fig. 2 Serial data from OGTTs. Active glucagon-like-peptide 1 (GLP-1) (a) and gastric inhibitory peptide (GIP) (b) are shown after ingestion of either
Diet Rite Cola™ ( with dashed line), Diet Mountain Dew™ ( with dotted line), 68 mg sucralose and 41 mg acesulfame-potassium in seltzer
water ( with dashed and dotted line) or seltzer water ( with solid line) 10 min prior to a 75 g oral glucose load. Active GLP-1 was augmented in
all three NNS conditions vs. the seltzer water condition. All data are expressed as mean ± standard error
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does not induce pronounced metabolic effects. How-
ever, GLP-1 secretion was enhanced after Diet Rite
Cola™, and a statistically non-significant, but poten-
tially biologically important increase of insulin was
observed.
These results are consistent with our prior findings
that Diet Rite Cola™ sweetened with sucralose and
acesulfame-potassium enhanced GLP-1 secretion in
healthy youth, as well as in young individuals with
type 1 diabetes [26]. In the current study, we observed
that neither sucralose alone nor the combination of
sucralose with ace-K augmented the incretin response.
Instead, only the ingestion of diet soda resulted in
higher GLP-1 concentrations. This suggests that either
the taste associated with diet soda or the effect of
other ingredients are required to stimulate GLP-1
(Additional file 1: Table S1). We did not examine
whether acesulfame-potassium in isolation elicits
these metabolic responses. This sweetener differs from
sucralose and aspartame in that it activates bitter taste
receptors at lower concentrations [30]. Furthermore,
the addition of aspartame in Diet Mountain Dew™ did
not alter the observed results.
Animal studies have shown that NNS upregulate glu-
cose transporters (GLUT2, SGLT1). However, we did
not find a change in glucose uptake when measuring 3-
OMG, which was added to the oral glucose load as a
tracer. This may be due to the large 75 g glucose load
administered, which may have ‘overloaded’ the system,
as all glucose ingested is eventually absorbed. We also
did not observe delayed gastric emptying, a known
downstream effect of increased GLP-1 secretion. This is
not entirely surprising, however, as the elevation of
GLP-1 observed in our study (20 % increase) was con-
siderably lower than what is typically observed follow-
ing pharmacologic elevation of GLP-1 via DPP4
inhibitors (100 % increase) [31].
Despite the lack of statistical significance, it is note-
worthy that all conditions with NNS given in combin-
ation resulted in marginally higher insulin AUCs (22-
25 %). Pepino et al. [21] observed similar results with
sucralose alone, and it is possible that her predomin-
antly obese, female study participants may explain
this difference. Interestingly, our participants in study
arm 2 had higher baseline insulin secretion and may
thus have been more susceptible to metabolic alter-
ations following NNS exposure. Whether the insulin
secretion observed in the current study and by Pe-
pino et al. [21] was stimulated directly by sweet taste
receptors on beta cells as shown in vitro [19] or via
other mechanism remains entirely speculative. How-
ever, if our results are sustained with chronic NNS
ingestion, then minor changes in insulin levels may
contribute to eventual weight gain, as insulin is an
anabolic hormone known to promote food intake and
fat storage.
As alluded to above, considerable differences in study
participants and methods may explain variable findings
reported in the literature. Age, obesity, weight history
Fig. 3 Serial data from OGTTs. Glucose (a), insulin (b), and C-
peptide (c) are shown after ingestion of Diet Rite Cola™ (
with dashed line), Diet Mountain Dew™ ( with dotted line),
68 mg sucralose and 41 mg acesulfame-potassium ( with
dashed and dotted line) or seltzer water ( with solid line).
Insulin AUCs were 22 to 25% higher following all three NNS
conditions vs. seltzer water (not statistically significant). All data are
expressed as mean ± standard error
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and prior experience with sweet taste influence sweet
taste perception [32–34] and hormonal responses. Dose,
volume, composition, route of administration, and tim-
ing of NNS also vary between studies. Furthermore,
dietary intake and physical activity may affect OGTT re-
sults, and are typically not standardized in acute studies.
Polymorphisms in sweet taste receptor genes may also
explain clinically relevant individual differences [35].
Our study was not designed to address the role of
carbonation. We also did not standardize meals and
physical activity prior to each visit and included indi-
viduals with a range of habitual NNS consumption.
Finally, we did not adjust for multiple comparisons
in the statistical analysis, and our study was not
powered to detect changes in insulin. An inherent
limitation of our study is also the inability to predict
the consequences of prolonged NNS consumption.
The strengths of our study include testing NNS at
varying doses, both in isolation and combined with
other ingredients in diet soda. This allowed us to dif-
ferentiate between potential effects due to the palat-
ability and ingredient composition of diet soda and
those due to NNS. The use of a crossover design
allowed for control of intra-individual differences.
Conclusions
The current study demonstrates that ingestion of diet
sodas containing sucralose and acesulfame-potassium
leads to subtle increases of glucose-stimulated GLP-1
release. While NNS only augmented GLP-1 in the
context of diet soda, sucralose and acesulfame-
potassium consistently augmented insulin levels even
when administered in isolation (seltzer), although the
effect was not statistically significant. Our findings reiter-
ate the need for prospective, well-controlled, prolonged
exposure trials to determine the role of diet soda and
NNS in metabolic health and to differentiate between in-
dependent effects of NNS and those which may be due to
Table 1 Characteristics of healthy adult volunteers





Age (years) 29.7 ± 7.6 27.4 ± 6.7 0.21
Female Gender 53 % 55 % 0.81
Race (%) 0.02
White 60 % 42 %
Black 37 % 32 %
Other 3 % 26 %
Body Mass Index (BMI, kg/m2) 25.8 ± 4.2 26.3 ± 7.5 0.77
Weight Status (%) 0.56
Normal Weight 53 % 58 %
Overweight 23 % 16 %
Obese 23 % 26 %
Glucose (umol/L) 4.6 ± 0.3 4.8 ± 0.35 0.08
Insulin (pmol/L) 32.7 ± 15.6 51.5 ± 42.1 0.03
C-Peptide (nmol/L) 0.4 ± 0.1 0.7 ± 0.3 0.0006
HOMA-2 0.9 ± 0.3 1.5 ± 0.7 0.0001
Hemoglobin A1c (%) 5.3 ± 0.3 5.2 ± 0.4 0.32
Triglycerides (mmol/L) 0.8 ± 0.3 1.1 ± 0.7 0.07
HDL (mmol/L) 1.5 ± 0.3 1.5 ± 0.4 0.87
LDL (mmol/L) 2.4 ± 0.7 2.4 ± 0.8 0.95
Total cholesterol (mmol/L) 4.3 ± 0.8 4.4 ± 0.9 0.61
NNS Beverage Consumption (%)a 0.005
Never 57 % 40 %
≥ 1/month 26 % 53 %
≥ 1/day 17 % 7 %
NNS Packet Use (%)a 0.52
Never 70 % 73 %
≥ 1/month 23 % 17 %
≥ 1/day 7 % 10 %
aDifferent questionnaires were used to assess NNS consumption in Study Arm
1 and Study Arm 2
bValues in bold reflect statistical significance using a cut-off of p<0.05
Table 2 Glycemic and hormonal responses to an OGTT are similar after pretreatment with sucralose








Active GLP-1 AUC (pmol/L/120 min) 1268.4 ± 936.9 1217.7 ± 960.2 1327.4 ± 857.7 1328.4 ± 953.2
Active GLP-1 Peak (pmol/L) 18.2 ± 12.9 16.3 ± 11.1 17.4 ± 10.5 18.5 ± 14.4
GIP AUC (pg/mL/120 min) 13478.2 ± 6328.9 13298.0 ± 5877.8 13646.9 ± 6351.8 13881.6 ± 6720.2
GIP Peak (pg/mL) 139.9 ± 68.3 145.8 ± 80.2 141.0 ± 72.0 143.7 ± 68.2
Glucose AUC (mmol/L/120 min) 750.1 ± 149.2 766.6 ± 148.1 744.8 ± 134.6 730.8 ± 130.7
Glucose Peak (mmol/L) 7.1 ± 1.6 7.3 ± 1.5 7.1 ± 1.4 7.0 ± 1.3
Insulin AUC (pmol/L/120 min) 38571.6 ± 13814.6 39984.9 ± 24316.9 37749.1 ± 16896.9 36437.9 ± 13553.3
Insulin Peak (pmol/L) 420.1 ± 185.6 414.6 ± 182.5 404.1 ± 196.4 374.2 ± 147.8
C-Peptide AUC (nmol/L/120 min) 274.7 ± 71.8 278.3 ± 70.1 272.3 ± 84.1 269.7 ± 614.7
C-Peptide Peak (nmol/L) 3.0 ± 0.8 3.2 ± 0.8 3.1 ± 1.1 3.0 ± 0.8
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other ingredients in diet soda and/or synergism between
sweeteners and other ingredients.
Additional files
Additional file 1: Table S1. Ingredients in diet sodas. (DOCX 11 kb)
Additional file 2: Figure S1. Serial data from OGTTs. Acetaminophen (A)
and 3-O-methyl glucose (3-OMG) (B) are shown after ingestion of either Diet
Rite Cola™ (red square), or seltzer water (blue circle) 10 min prior to a
75 g oral glucose load. (PDF 321 kb)
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